Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Several key aspects differentiate our library:
partner
Reaxense
upacc
P19388
UPID:
RPAB1_HUMAN
Alternative names:
DNA-directed RNA polymerase II 23 kDa polypeptide; DNA-directed RNA polymerase II subunit E; RPB5 homolog; XAP4
Alternative UPACC:
P19388; B2R6L4; D6W5Y1; O43380; Q6PIH5; Q9BT06
Background:
DNA-directed RNA polymerases I, II, and III subunit RPABC1, also known as DNA-directed RNA polymerase II 23 kDa polypeptide, plays a pivotal role in the transcription of DNA into RNA, utilizing ribonucleoside triphosphates. It is a key component of RNA polymerases I, II, and III, involved in synthesizing ribosomal RNA precursors, mRNA precursors, and various functional non-coding RNAs. Its unique structure, featuring mobile elements, allows for efficient interaction with DNA templates.
Therapeutic significance:
Understanding the role of DNA-directed RNA polymerases I, II, and III subunit RPABC1 could open doors to potential therapeutic strategies. Its central role in transcription suggests that modulating its activity could influence gene expression patterns involved in various diseases.